Randomized trial · people
Tirzepatide: sleep apnea gains beat placebo by week 20 in SURMOUNT-OSA
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this trial, tirzepatide improved pAHI from baseline by Week 4, took until Week 20 to clearly beat placebo, and gains were larger in people who lost more weight.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2025
- Journal
- Sleep Med
What they tested
The team asked how quickly tirzepatide improved sleep apnea measures and how closely those improvements tracked weight loss.
How the study was done
A post hoc analysis, meaning one planned after the main results, of two 52-week, randomized, double-blind, placebo-controlled Phase 3 studies in adults with obstructive sleep apnea. It used linear regression to look at effects tied to weight loss and effects not tied to it.

Model. Individual results vary.
What they found
In Study 1, readings from a sleep device, the WatchPAT 300, matched results from polysomnography, a full overnight sleep test. On the device, tirzepatide improved the peripheral apnea-hypopnea index (pAHI, a count of breathing pauses and shallow breaths per hour of sleep) compared with baseline as early as Week 4. The gap versus placebo, a dummy treatment, did not become significant until Week 20, both for pAHI and for sleep apnea-specific hypoxic burden (SASHB, how much oxygen levels fall during breathing events). In both studies, larger weight loss went along with larger changes in AHI and SASHB.
What it doesn’t show
This was a post hoc analysis, so it was not the trial's main test. It shows that improvement went along with weight loss, but it could not separate the effect of weight loss from other effects of tirzepatide. The authors say more research is needed on that question.
The paper
Malhotra et al. Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight. Sleep Med. 2025.
The compound
More studies on Tirzepatide
- Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZERandomized trial · people · 2026
- Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeksRandomized trial · people · 2026
- Dulaglutide: switching to tirzepatide beat dose escalation on HbA1cRandomized trial · people · 2025
- Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: about 75% of weight lost was fat in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: most reached a weight plateau by week 72 in SURMOUNT-1Randomized trial · people · 2025
- Every study on Tirzepatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.